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M O L E C U L A R  B I O L O G Y
A common genetic variant of a mitochondrial RNA 
processing enzyme predisposes to insulin resistance
Giulia Rossetti1,2,3, Judith A. Ermer1,2,3, Maike Stentenbach1,2,3, Stefan J. Siira1,2,3, Tara R. Richman1,2,3, 
Dusanka Milenkovic4, Kara L. Perks1,2,3, Laetitia A. Hughes1,2,3, Emma Jamieson5, 
Gulibaikelamu Xiafukaiti6, Natalie C. Ward7, Satoru Takahashi6, Nicola Gray8,  
Helena M. Viola9, Livia C. Hool9,10, Oliver Rackham1,2,11,12,13, Aleksandra Filipovska1,2,3,13,14*
Mitochondrial energy metabolism plays an important role in the pathophysiology of insulin resistance. Recently, 
a missense N437S variant was identified in the MRPP3 gene, which encodes a mitochondrial RNA processing en-
zyme within the RNase P complex, with predicted impact on metabolism. We used CRISPR-Cas9 genome editing 
to introduce this variant into the mouse Mrpp3 gene and show that the variant causes insulin resistance on a high-fat 
diet. The variant did not influence mitochondrial gene expression markedly, but instead, it reduced mitochondrial 
calcium that lowered insulin release from the pancreatic islet  cells of the Mrpp3 variant mice. Reduced insulin 
secretion resulted in lower insulin levels that contributed to imbalanced metabolism and liver steatosis in the 
Mrpp3 variant mice on a high-fat diet. Our findings reveal that the MRPP3 variant may be a predisposing factor to 
insulin resistance and metabolic disease in the human population.
INTRODUCTION
Insulin resistance and impaired insulin secretion are the main de-
fects in type 2 diabetes, projected to be the seventh leading cause of 
death by 2030 (1). Impaired energy production, use of energy stores, 
and mitochondrial dysfunction are major features in metabolic dis-
eases. Nevertheless, it remains uncertain how mitochondrial dys-
function can cause, contribute to, or result in insulin resistance and 
metabolic disease. Mutations and variations in genes encoding mito-
chondrial proteins have been shown to contribute to common 
metabolic diseases such as type 2 diabetes, insulin resistance, 
obesity, and cancers resulting from metabolic dysfunction (2–4). 
There is growing evidence from genetic and genome-wide associa-
tion studies (GWAS) that genetic variation in mitochondrial DNA 
(mtDNA) contributes to these common metabolic diseases (5); how-
ever, there has been essentially no in vivo functional validation for 
these findings. Recently, a missense variant (rs11156878, Asn437Ser) 
was identified in the mitochondrial ribonuclease P subunit 3 (MRPP3) 
gene, which encodes an RNA binding protein suggested to be re-
sponsible for 22% of the variance in mitochondrial tRNA position 9 
methylation in up to 19% of the population (6). This study predicted 
that the variant may have likely consequences on metabolism (6); 
however, this genetic association has not been functionally validated 
and its role in metabolism remains unknown.
The mitochondrial genome codes for 13 proteins that are all 
essential components of the electron transport chain and the adenos-
ine triphosphate (ATP) synthase, which are responsible for energy 
production by oxidative phosphorylation (OXPHOS). Mutations in 
mtDNA most commonly lead to mitochondrial diseases and, in 
some instances, contribute to the onset and development of diabetes 
due to impaired insulin secretion (7,  8), although the molecular 
mechanisms of these pathologies are unclear and are predominantly 
thought to involve OXPHOS dysfunction. Human mtDNA is circular 
and largely devoid of noncoding sequences, encoding 11 mRNAs, 22 
transfer RNAs (tRNAs), and 2 ribosomal RNAs (rRNAs) that are 
transcribed as large polycistronic transcripts covering almost the 
entire length of each strand of the genome (9). The lack of introns 
in mtDNA genes has eliminated the requirement for splicing; in-
stead, the tRNA genes, which are interspersed between mRNA and 
rRNA coding genes, enable recruitment of tRNA processing enzymes 
to produce the individual transcripts (10). Mitochondrial RNA pro-
cessing involves cleavage at the 5′ end of tRNAs by ribonuclease 
(RNase) P (11, 12) and cleavage of the 3′ tRNA ends by the mito-
chondrial RNase Z, encoded by the ELAC2 gene (13). Impaired 
RNA processing has profound effects on mitochondrial and nuclear 
gene expression, protein synthesis, and, consequently, the assembly 
and function of the respiratory chain, causing premature death (12–14).
The mitochondrial RNase P is a proteinaceous complex, devoid 
of a catalytic RNA and composed of three proteins: mitochondrial 
RNase P protein 1 (MRPP1, also known as tRNA methyltransferase 
10C homolog, TRMT10C), MRPP2 or HSD17B10 (hydroxysteroid 
17- dehydrogenase 10), and MRPP3 also known as the protein only
RNase P catalytic subunit (PRORP) (11). Although MRPP3 has the
catalytic RNA cleavage function, all three proteins are required for
RNase P activity (11). Dysfunction of any component of the RNase P can 
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affect RNA processing with dire consequences for energy metabo-
lism (12, 14, 15). This is evident from loss of, or mutations in, RNase 
P components that cause embryonic lethality in mice (12) or lead to 
severe multisystem disorders and premature death in humans by 
disruption of 5′ tRNA processing (14, 15). In addition to facilitating 
tRNA processing within the RNase P complex, MRPP1 and MRPP2 
have other roles in mitochondria. MRPP1 moonlights as a methyl-
transferase that modifies guanine or adenine at position 9 of mitochon-
drial tRNAs (16, 17), and MRPP2 is a member of the short-chain 
dehydrogenase superfamily, required for branched chain amino acid 
(BCAA) and steroid hormone metabolism (18).
The influence of nuclear genetic variation on the mitochondrial 
transcriptome and how it can predispose to common metabolic dis-
ease has not been investigated by functional studies or using in vivo 
models previously. Therefore, we sought to investigate how the vari-
ant in the MRPP3 gene affects the mitochondrial transcriptome and 
function. We used CRISPR-Cas9 genome editing to introduce the 
rs11156878 variant in the mouse Mrpp3 gene and show that, on a 
high-fat diet (HFD), the mutation desensitizes pancreatic  cells by 
perturbing insulin secretion. Our work provides functional and mech-
anistic evidence for diet-specific effects of a common variant in the 
human population that may predispose to insulin resistance.
RESULTS
The Mrpp3 variant causes insulin resistance  
in mice fed an HFD
The Asn437Ser variant predicted by GWAS to affect metabolic 
function and the mitochondrial epitranscriptome is present at variable 
frequencies in the human population, ranging from highest at 15 to 
19% in European, followed by 6 to 11% in Asian, and lowest at 3 to 
6% in African populations (gnomAD, 1000 Genomes Project; Fig. 1A). 
The asparagine at position 437 is conserved from humans to rodents 
(Fig. 1B). Atomic structures of the MRPP3 or PRORP enzyme revealed 
that it consists of a metallonuclease domain that carries out the 
endonuclease cleavage of tRNAs and a central linker and five tandem 
pentatricopeptide repeat (PPR) RNA binding domains, which are 
involved in tRNA binding (19–21). We used the atomic structures 
to model the Asn437Ser variant and show that it is located on the 
surface of the catalytic domain, well away from the catalytic site of 
MRPP3 (Fig.  1C). The Asn437Ser variant does not alter the local 
charge distribution on the surface of the catalytic domain (Fig. 1D).
We used CRISPR-Cas9 technology to knock in the equivalent 
Asn434Ser variant into the mouse Mrpp3 gene to investigate its effect 
on metabolism, the mitochondrial transcriptome, and energy pro-
duction compared to the wild-type Mrpp3 gene. We bred the mice to 
produce homozygous variant Mrpp3 mice (N434S) and homozygous 
wild-type Mrpp3 mice (wt), and their genotypes were confirmed by 
Sanger sequencing (Fig. 1E). The mouse missense mutation was in an 
identical amino acid as in the human MRPP3 gene and in a highly 
conserved region of MRPP3 that did not affect its abundance com-
pared to the wild-type MRPP3 (fig. S1A). To understand the role of 
the Asn434Ser change in metabolism, we fed male wt mice and 
N434S littermates either a normal chow diet (NCD) or an HFD for 
14 weeks. The N434S mice had a leaner phenotype with a lower body 
weight compared to the wt littermates on the NCD, but there was 
no difference in the body weight between the two genotypes on the 
HFD (Fig. 1F and fig. S1B). Glucose tolerance testing (GTT) revealed 
that the N434S mice were mildly glucose intolerant on both diets, 
compared to the wt control mice (Fig. 1G). Insulin tolerance testing 
(ITT) showed that the N434S mice fed on the HFD were desensi-
tized to insulin compared to the wt mice (Fig. 1H). These findings 
indicate that the Asn434Ser variant may predispose to insulin resist-
ance on an HFD.
An HFD in the N434S mice lowers circulating insulin levels, 
increases pancreatic islet size, and results in liver steatosis
The diet-specific effects of the N434S variant on insulin tolerance 
prompted us to investigate the pancreas because of its major role in 
glucose-stimulated insulin secretion and its target organs: the liver, 
skeletal muscle, and adipose tissue by hematoxylin and eosin (H&E) 
staining (Fig. 2 and fig. S2A). The pancreata and livers had the most 
obvious morphological changes in the N434S mice compared to the 
wt mice (Fig. 2). In the NCD-fed N434S mice, the pancreata had 
minor patches of early onset acini necrosis (Fig.  2A), whereas 
pancreata of the HFD-fed N434S mice showed severe loss of acini 
structure, acute necrosis likely due to the enzyme release of the 
acini, and larger islets of Langerhans compared to wt mice (Fig. 2A). 
The HFD- fed wt mice had low levels of necrosis, but the general 
tissue structure was unaffected and the acini had normal appearance 
(Fig. 2A). Pancreatic islet hyperplasia was consistent with reduced 
circulating insulin levels in the N434S mice that were fed an HFD 
compared to wt mice (Fig. 2B) and consistent with previous findings 
that larger islets of Langerhans are associated with lower insulin 
secretion (22). There were no major differences between the livers 
of the NCD-fed N434S and wt mice; however, H&E and Oil Red O 
staining revealed greater accumulation of lipid droplets in the livers 
of N434S mice fed an HFD, compared to wt mice on the same diet, 
indicating the presence of liver steatosis (Fig.  2C). Ectopic lipid 
storage in nonadipose tissue such as the liver has been identified in 
insulin resistance (23) and is consistent with the mild insulin resis-
tance of the N434S mice on the HFD. In the skeletal muscle from 
N434S mice compared to the wt mice fed on an NCD, there was a 
slight increase in endomysial connective tissue and a mild presence 
of necrotic fibers, while on the HFD, there were some centralized 
nuclei in the skeletal muscle N434S mice compared to the wt mice 
(fig. S2A). There were signs of inflammation in the white adipose 
tissue of N434S mice compared to the wt mice fed on an NCD, while 
the HFD resulted in increased adipocyte size in the N434S mice 
compared to the wt mice (fig. S2B).
Circulating levels of albumin were reduced in the N434S mice 
fed on an NCD but were increased in the N434S mice on the HFD 
compared to their respective wt littermates (Fig. 2D). The marker of 
liver steatosis, alanine amino transferase (ALT), was significantly 
increased in the HFD-fed N434S mice compared to controls, further 
validating the Oil Red O staining findings. There were no differences 
in the high-density lipoprotein (HDL) and triacylglycerol (TAG) levels 
between the N434S and wt mice on either diet; however, cholesterol 
and low-density lipoprotein (LDL) levels were reduced in the N434S 
on the NCD and increased in the variant mice on the HFD (Fig. 2D), 
consistent with the predisposition of the N434S variant to insulin 
resistance on an HFD. Next, we measured the levels of circulating 
short-chain fatty acids (SCFA) in the serum, produced by the gut 
microbiota that have been used as markers of metabolic changes 
(24–26). The levels of the three SCFA were not different between the 
N434S and wt mice on an NCD (Fig. 2E). However, the levels of butyrate, 
shown to protect from diet-induced obesity and metabolic disorders 
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Fig. 1. The N434S mice develop insulin resistance when fed on a HFD. (A) Frequencies of the MRPP3 N437S single-nucleotide polymorphism (chr14:35266761 A>G, 
GRCh38.p12)(rs11156878) across different human populations. (B) Conservation of the MRPP3 protein sequence surrounding the N437S variant amino acid (red) is highlighted 
with residues identical to those in human sequence boxed in blue. (C) The location of N437 (red) is shown within the modeled structure of the human MRPP3 enzyme in 
complex with a tRNA substrate. The catalytic domain of MRPP3 is shown in blue, its four active site aspartates in orange, the PPR domain in green, and the bound tRNA in 
purple. (D) Close-up views of the N437 residue or N437S variant of MRPP3. The surface charge distribution is colored according to the local electrostatic potential (blue, 
+5 kT; red, −5 kT). (E) The N434S mutation in the Mrpp3 gene was confirmed by Sanger sequencing of PCR amplicons from homozygous N434S and wt littermates. (F) Body 
weight of NCD and HFD-fed wt and N434S mice measured at 20 weeks of age. (G) Glucose tolerance tests (GTT) and (H) insulin tolerance tests (ITT) were carried out at 12 
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Fig. 2. The N434S variant leads to reduced circulating insulin and hepatosteatosis in HFD-fed mice. (A) H&E staining of pancreata from 20-week-old mice fed 
NCD show enzymatic necrosis of the acinar cells (yellow circles) in the N434S mice. Sections were visualized at ×10 (left), ×20 (right), or ×40 magnification (bottom). Scale 
bars, 100 and 25 m. (B) Circulating insulin levels were measured in serum obtained from fasted 20-week-old N434S and wt (n = 4) mice fed either a NCD or a HFD. (C) H&E 
staining of liver sections from 20-week-old wt and N434S mice fed a NCD and a HFD (left) and Oil Red O staining (right). Magnification is ×10 or ×20. Scale bars, 100 m. 
(D) Sera of 20-week-old wt and N434S mice fed a NCD or a HFD (n = 4) were analyzed for circulating albumin, ALT, TAGs, LDL, HDL, and cholesterol levels. (E) Sera of 
20-week-old wt and N434S mice fed a NCD or a HFD (n = 9) were analyzed for short-chain fatty acids (SCFA) levels: acetate, butyrate, and propionate. Values are means ± 
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in the N434S mice compared to controls when they were fed an HFD 
(Fig. 2E), where previously increased acetate levels have been shown 
to induce metabolic syndrome (26). This is consistent with all the 
findings that the N434S variant reduces  cell sensitivity induced by 
an HFD and adversely affects gut microbiota.
We investigated the activation of the cellular insulin signaling 
pathway by immunoblotting against the serine/threonine protein 
kinase Akt and its activated form, phospho-Akt, either in basal con-
ditions or following terminal insulin treatment. We found that both 
under basal conditions and after insulin treatment, Akt phosphoryl-
ation was not altered in the livers of the N434S and wt mice on either 
diets (Fig. 3, A and B), suggesting that insulin resistance did not 
involve changes in Akt signaling in the liver. In the pancreata, 
under basal conditions, Akt phosphorylation was increased in the 
N434S mice on NCD, compared to wt mice. However, on the HFD, 
the phosphorylation of Akt in the N434S mice was comparable to 
the wt mice (Fig. 3A). Insulin stimulation reduced Akt phosphoryl-
ation in the N434S mice fed a NCD, possibly as a compensatory 
response, and the levels of phospho-Akt were similar between the 
N434S and wt mice fed a HFD (Fig. 3B). There were no differences 
in the levels of the glucose transporter GLUT2, which can be acti-
vated following insulin stimulation, in the livers or pancreata of the 
N434S and wt mice on either diet (Fig. 3C). This indicated that 
impaired glucose uptake in the liver and by pancreatic  cells is not 
the cause of insulin resistance in the N434S mice. Because increased 
Akt phosphorylation in the pancreata N434S mice may affect mech-
anistic target of rapamycin (mTOR) activation via phosphorylation 
of S6, we used immunoblotting and found that on a NCD, S6 phos-
phorylation was increased in the N434S mice compared to controls 
(Fig. 3D). However, on an HFD, S6 phosphorylation was significantly 
reduced in N434S mice (Fig. 3D), suggesting that insulin resistance 
resulted in down-regulation of the mTOR pathway via S6. In the skeletal 
muscle from N434S mice fed an HFD, Akt phosphorylation was sig-
nificantly reduced along with the levels of GLUT4 compared to 
control mice (fig. S2C), and this was due to reduced glucose uptake 
(fig. S2D), which resulted in insulin resistance in the N434S mice.
Next, we investigated the effects on mitochondrial respiration 
and whether lipid accumulation in the liver was associated with a 
preference toward the use of glucose over fatty acids as substrates 
for energy production and in response to the different diets. We 
measured both oxygen consumption via the S-linked pathway by 
stimulating respiration using succinate and -oxidation rates via 
the F-linked pathway using palmitoylcarnitine in isolated liver mito-
chondria from N434S and wt mice. Oxygen consumption via the 
S-linked pathway was not affected in the NCD-fed N434S mice com-
pared to controls (fig. S3A). However, there was a reduction in the 
oxygen consumption in the Leak (L) and OXPHOS (P) states in the 
F-linked pathway (fig. S3B), indicating that fatty acid oxidation in 
the N434S mice was reduced on the NCD. The HFD caused a signifi-
cant increase in respiration via the S-linked pathway in the N434S 
mice (fig. S3C), whereas fatty acid oxidation was not significantly 
affected in the wt and N434S mice, but there was mild uncoupling 
of OXPHOS in the N434S mice on the HFD (fig. S3D).
To determine whether the changes in the NCD liver S-linked 
pathway were driven by a decreased influx of long-chain fatty acids 
(LCFAs) inside mitochondria, we analyzed the levels of the carnitine 
palitoyltransferase complex (CPT), responsible for the transfer of 
LCFAs inside mitochondria, and specifically its subunit carnitine 
palmitoyltransferase II (CPTII). The levels of CPTII were not altered 
in the livers of the wt and N434S mice on either diet, suggesting that 
only the use but not the uptake of fatty acids in mitochondria was 
affected by the variant (fig. S3E). Together with the oxygen consump-
tion findings, we show that liver mitochondria of N434S mice prefer 
to use glucose over fatty acids for ATP production, which likely 
contributes to the development of liver steatosis.
Insulin resistance in the N434S mice is not the result 
of mitochondrial posttranscriptional RNA modification
To understand the metabolic differences between the wt and N434S 
mice, we investigated how the variant affects the molecular role of 
MRPP3. RNA sequencing of pancreatic islet cells revealed that the 
MRPP3 variant did not affect mitochondrial RNA processing when 
the mice were fed on a NCD (Fig. 4A). However, we observed small 
increases in unprocessed tRNA junctions across the entire mito-
chondrial transcriptome in the N434S mice compared to controls 
fed on an HFD (Fig. 4A). We used quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) to confirm that on the NCD, 
the variant did not affect RNA processing, but on the HFD, there 
were increases in the unprocessed mitochondrial tRNA junctions in 
the pancreata (Fig. 4B). Mitochondrial RNA processing was not 
significantly affected in the livers of the N434S and wt mice on either 
diet (fig. S4A), but there were small reductions in the stability of 
some mature mtRNAs (fig. S4B). This indicated that the variant has 
a greater effect in the pancreas that is consistent with the most 
significant changes found in the pancreas including increased islet 
size, reduced insulin levels, and insulin resistance.
We used small RNA sequencing to determine the effects of the 
N434S variant on the modification of position 9 of mitochondrial 
tRNAs by measuring the increased sequencing error rate at this 
position in pancreatic islet cells from wt and N434S mice (Fig. 4C). 
We found that the MRPP3 variant does not affect the methylation 
status of mitochondrial tRNAs at position 9, and it does not affect 
the stability and abundance of mt-tRNAs (Fig. 4, C and D). Therefore, 
the variant does not affect the posttranscriptional modification of 
mt-tRNAs (6), which is entirely consistent with the role of the MRPP3 
enzyme in tRNA cleavage and not tRNA modification (17).
We investigated the steady-state levels of OXPHOS proteins in 
the pancreata and livers of the wt and N434S mice on both diets by 
immunoblotting. There were no changes in the levels of OXPHOS 
proteins in the livers of the wt and N434S mice on both diets (fig. 
S4C), consistent with the minimal effects on mtRNAs. Similarly, the 
OXPHOS protein levels were not different in the pancreata of the 
wt and N434S mice on either diet, with the exception of the in-
creased levels of ATP5A subunit of complex V in the N434S mice 
fed an HFD (Fig. 4E). In addition, there were no changes between the 
wt and N434S mice on either diet in the heart (fig. S5A) or skeletal 
muscle (fig. S6A) of the OXPHOS proteins. There were no changes 
in MRPP2, lipid and glucose import transporters in the hearts (fig. 
S5B), and skeletal muscle of the variant and control mice (fig. S6, 
B and C), further indicating that the variant influences predomi-
nantly pancreatic function but not its target organs. Furthermore, 
these data indicate that the N434S variant does not affect the catalytic 
function of MRPP3; thereby, it does not compromise mitochondrial 
RNA processing sufficiently to affect normal OXPHOS levels and 
function. Therefore, the N434S variant does not cause insulin resistance 
via changes in OXPHOS in contrast to what has been previously 
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Fig. 3. Changes in Akt and mTOR signaling but not the expression of glucose transporters in Mrpp3-N434S mice. Liver and pancreas whole tissue lysates (30 g) 
from 20-week-old N434S mice and wt mice fed a NCD or a HFD were immunoblotted against antibodies to investigate the endogenous levels of Akt and its phosphory-
lated form (Ser473) under basal conditions (A) and following insulin exposure (terminal insulin) (B), where the mice were injected with insulin (1 U/kg) and euthanized 
after 5 min before the tissue was collected. Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as a loading control. (C) Immunoblotting against the glucose 
transporter proteins (GLUT2) in livers and pancreata lysates (30 g) from 20-week-old N434S mice and wt mice fed a NCD or a HFD. GAPDH was used as a loading 
control. (D) Immunoblotting against the S6 and phospho-S6 in pancreata lysates (30 g) from 20-week-old N434S mice and wt mice fed a NCD or a HFD. GAPDH was used 
as a loading control. Relative abundance of proteins was measured using Image Studio Lite and normalized to GAPDH. The data are representative of results obtained 
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Fig. 4. Mitochondrial RNA processing and posttranslational tRNA modification are not functionally affected by the N434S variant. (A) A complete map of mtRNA 
abundance and mean log2 fold change (FC) [(KOmean/Ctrlmean)] determined by RNA sequencing coverage in pancreatic islets from 20-week-old N434S and wt mice fed 
a NCD or HFD (n = 3). Increases are shown in red and decreases in blue. The log2 fold changes range from −2.5 to 1. (B) qRT-PCR was used to measure mitochondrial RNA 
junctions in pancreata from 20-week-old N434S and wt mice either fed a NCD or a HFD (n = 3). Data were normalized to 18S rRNA. Error bars are means ± SEM. (C) Relative 
rate of nonreference bases, indicative of modification, at the ninth mt-tRNA position relative to a nonreference tRNA position and (D) relative tRNA abundance, determined 
by small RNA sequencing in pancreatic islets from 20-week-old N434S and wt mice fed a HFD (n = 3). Data were normalized to total library size. (E) Pancreatic mitochon-
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The MRPP3 N434S variant has reduced association 
with MRPP2 and the cation transporter LETM1
To identify proteins that are differentially associated with either the 
wild-type or variant form of MRPP3, we performed a proximity- 
biotinylation assay (BioID) followed by affinity purification and mass 
spectrometry. Before proceeding with the assay, we successfully 
assessed in 143B cells that the hemagglutinin (HA) tag fused to 
MRPP3 and MRPP3-N434S variant protein did not interfere with 
the normal expression and localization of the protein inside mito-
chondria (fig. S7). BioID identified that the MRPP3 variant caused 
reduced association with the leucine zipper and EF-hand contain-
ing transmembrane protein 1 (LETM1) (Fig. 5A). To validate the 
BioID result and explore the interactions between LETM1 with the 
RNase P complex subunits, we used a bimolecular fluorescence 
complementation assay (29) where LETM1 was fused to the N-terminal 
portion of Venus and each of the RNase P protein subunits, MRPP1, 
MRPP2, or MRPP3, was fused to the C terminus of Venus. Cells 
transfected with both N-terminal and C-terminal fusions of the 
proteins that interact with each other would enable the formation of 
a fluorescent Venus protein that was detected by fluorescence flow 
cytometry. We show that the glutathione S-transferase 1 (GST1) in 
combination with MRPP1 as a control was not fluorescent above 
background (Fig. 5B). We found that the direct association of both 
the wt and N434S MRPP3 with LETM1 is similar and relatively 
weak, and there is no association of LETM1 with MRPP1 (Fig. 5B). 
In contrast, we identified that there is a very strong association of 
LETM1 with MRPP2, and it is likely that through this interaction that 
the RNase P complex associates with LETM1 (Fig. 5B). To test this 
hypothesis, we investigated the association of the wt and N434S 
MRPP3 with the other two RNase P subunits (Fig. 5C). We show that 
the interaction of the N434S MRPP3 with MRPP2 is reduced 
compared to the interaction between the wt MRPP3 with MRPP2 
(Fig. 5C). In contrast, the interactions between MRPP1 and the wt 
or N434S variant were comparable, albeit weaker compared to the 
MRPP2-MRPP3 association. To confirm this result, we used immu-
noprecipitation of HA-tagged wt or N434S MRPP3 and identified 
that the association of the MRPP3 variant protein was reduced with 
LETM1 and MRPP2 in NIH-3T3 cells (Fig. 5D). These three inde-
pendent methods indicate that the RNase P complex associates with 
LETM1 and that the N434S variant reduces the association of 
MRPP3 with MRPP2, which, in turn, associates with LETM1.
To evaluate the effects of the wt and N434S MRPP3 on levels of 
LETM1 and MRPP2, we used immunoblotting and found that both 
LETM1 and MRPP2 levels were reduced in the pancreata of N434S 
mice fed a NCD, and both were increased in the HFD-fed N434S 
mice compared to their respective controls (Fig. 5E and fig. S8A). 
Given the strong interaction between LETM1 and MRPP2, our find-
ings suggest that the levels of these proteins are dependent on or 
coregulated with each other as they associate closely together in the 
pancreas. In the livers of the N434S mice, the levels of LETM1 and 
MRPP2 were not affected on the NCD; however, the levels of these 
proteins were reduced on the HFD (fig. S8B). We also investigated 
the levels of other mitochondrial RNA and DNA binding proteins 
that are required for mtRNA stability, such as leucine rich pentatri-
copeptide repeat containing protein (LRPPRC), or required for mtDNA 
stability, such as Mitochondrial transcription factor A (TFAM), and 
found that their levels were largely unaffected in the pancreata and 
livers of the wt and N434S mice on either diet (fig. S8, C and D), further 
confirming that the gene expression machinery in mitochondria is 
not affected by the variant. The levels of the mitochondrial calcium 
uniporter (MCU) were also not affected by the variant on either diet 
(fig. S8E), indicating that the general pathways for mitochondrial 
calcium homeostasis are maintained (30, 31).
Because mitochondrial RNA processing was not affected, we in-
vestigated whether changes in MRPP2 levels affect its function in 
BCAA metabolism. We used mass spectrometry to quantify amino 
acid levels in pancreata and sera from wt and N434S mice on both 
diets (Fig. 5, F and G, and fig. S9). We found significant reduction 
of BCAA in both pancreata and sera from the HFD-fed N434S mice 
(Fig. 5, F and G), particularly isoleucine, where MRPP2 is elevated 
and has a direct role in its degradation (32). The reduction of BCAA 
in the HFD-fed N434S mice could also be a consequence of reduced 
mTOR activity.
The MRPP3 variant impairs calcium availability required 
for glucose-stimulated insulin release on an HFD
LETM1 is a mitochondrial cation transporter that has been shown 
to affect calcium and potassium levels (33–36). Changes in cytosolic 
calcium levels play an essential role in pancreatic  cell function 
because they trigger the exocytosis of insulin granules (31, 37). Be-
cause the N434S mice fed an HFD had reduced circulating insulin 
levels, we sought to investigate changes in calcium levels in response 
to an NCD or HFD that may affect insulin release. We measured 
calcium levels using Fura-2 in pancreatic islet cells isolated from wt 
and N434S mice fed an NCD and HFD under basal conditions and 
after glucose treatment to induce insulin release (Fig. 6A). Glucose 
stimulation increased calcium levels in the pancreatic islet cells of 
wt and N434S mice fed on an NCD required for insulin release, albeit 
this increase was significantly greater in the N434S mice, likely a 
consequence of an insulin hypersecretion during fasting in these 
mice (Fig.  6A). The calcium levels in response to glucose were 
significantly increased relative to basal levels in the pancreatic islet 
cells of wt and N434S mice fed an HFD; however, the calcium levels 
in the N434S mice fed an HFD and required for insulin secretion 
were markedly reduced compared to the NCD (Fig. 6A). We used 
Rhod-2 to measure mitochondrial calcium levels and found that 
they followed the changes in cytoplasmic calcium (Fig. 6, A and B). 
Mitochondrial calcium levels were increased in both basal and 
glucose-stimulated pancreatic islet cells from N434S mice compared 
to wt mice on an NCD (Fig. 6B). In contrast, mitochondrial calcium 
levels were reduced in response to glucose stimulation in the N434S 
mice compared to wt mice fed an HFD (Fig. 6B), consistent with re-
duced insulin sensitivity in the HFD-fed N434S mice. Because LETM1 
has also been characterized as a potassium antiporter (31, 35, 38), 
we measured potassium levels in the serum of wt and N434S mice 
and show that there is significant reduction in circulating potassium 
levels in the N434S mice compared to controls on an HFD (Fig. 6C). 
We used JC-1 to measure the changes in the mitochondrial mem-
brane potential in pancreatic islet cells and found that it was signifi-
cantly elevated in the N434S mice fed an NCD (fig. S10A), possibly 
a consequence of reduced LETM1 levels and consequent imbalance 
in cation transport, that is subsequently equalized on the HFD as 
the LETM1 levels were increased.
To investigate whether changes in calcium affect insulin abun-
dance, we measured insulin levels in the pancreata of wt and N434S 
mice on both diets and found that the N434S variant did not affect 
insulin production (Fig. 6D). This was further validated by fluores-
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Fig. 5. The MRPP3 N434S variant reduces its association with LETM1 via MRPP2. (A) BioID of BirA*-tagged wt or N434S MRPP3 expressed in HeLa cells and the associated 
proteins were detected by mass spectrometry. Mitochondrial-targeted BirA* (mt-BirA*) was used as a control. (B) Average Venus intensities normalized to red fluorescent 
protein (RFP) intensity for interactions between LETM1 and the wt or N434S MRPP3, as well as MRPP1 and MRPP2 in NIH-3T3 cells determined by fluorescence-activated 
cell sorting. GST1 was used as a negative control. Data are shown as a percent change compared to the respective control. (C) Average Venus intensities normalized to 
RFP intensity comparing interactions between the wt and N434S MRPP3 with MRPP1 or MRPP2. GST1 was used as a negative control. (D) Immunoprecipitation of HA-tagged 
MRPP3 and MRPP3-N434S expressed in NIH-3T3 cells and immunoblots of the fractions from the immunoprecipitation against LETM1 and MRPP2. HA-tagged SOD2 was 
used as a control bait. (E) The levels of MRPP2 and LETM1 were measured by immunoblotting of pancreatic mitochondria and normalized to porin. Amino acid content 
was measured in pancreata (F) or serum (G) by mass spectrometry. All data are representative of results obtained from at least three experiments or three mice from 
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Fig. 6. The MRPP3 N434S variant results in reduced mitochondrial calcium and insulin secretion. Cellular (A) and mitochondrial (B) calcium levels were analyzed in 
isolated pancreatic  cells using Fura-2 or Rhod-2 fluorescent microscopy, respectively, under basal conditions and after exposure to glucose. (C) Potassium levels were 
measured in serum and (D) insulin levels were measured in pancreata by enzyme-linked immunosorbent assay (ELISA). (E) Insulin and glucagon levels were measured in 
pancreata by fluorescent immunohistochemistry. Hoechst staining was used to visualize the nuclei. (F) Glucose-stimulated insulin secretion was measured in pancreatic 
islet cells in the presence of low and high glucose, and total insulin levels were measured in the cell pellets as controls using an ELISA. All data are representative of results 
obtained from at least three mice from 20-week-old N434S mice and wt mice fed a NCD or a HFD. Error bars are SEM *P < 0.05, **P < 0.01, and ***P < 0.001, Student’s t test. 
(G) Reduced RNase P association with LETM1 may affect calcium transport into mitochondria and the cellular calcium availability required for insulin secretion. The 
increased calorie intake from the HFD causes an increased requirement for insulin secretion, and the calcium levels are not sufficient to trigger increased insulin secretion 
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that their levels were not affected by the N434S variant on either diet 
(Fig. 6E). We did not observe any inflammation markers in the liv-
ers or pancreata in the wt and N434S mice on both diets (fig. S10B), 
indicating that this did not play a role in insulin resistance or dam-
age of the pancreas. The ratio of the autophagy marker LC3A/B isoforms 
(Light Chain 3 A/B isoforms I and II) was not different between in 
the wt and N434S mice fed on a NCD; however, on the HFD, the 
ratio between and longer and shorter isoform of LC3A/B was in-
creased in the pancreata of N434S mice, indicative of autophagy (fig. 
S10C) that was consistent with increased necrosis identified by 
histology in these mice and the proposed role for MRPP3 in mito-
chondrial stress response (39).
Because insulin abundance was not affected, we investigated whether 
changes in calcium affected insulin release. We measured glucose- 
stimulated insulin release from the pancreatic islet cells from wt and 
N434S mice on either diet to determine whether the secretion of 
insulin was impaired. We found that the insulin secretion was 
perturbed in the N434S mice fed on an NCD compared to wt mice, 
consistent with their increased calcium levels and hypersecretion of 
insulin sensitivity (Fig. 6F). In contrast, the N434S mice fed on an 
HFD had significantly lower insulin secretion capacity compared to 
their respective controls (Fig. 6F), consistent with reduced calcium 
levels, lower circulating insulin levels, and insulin resistance. The 
cell pellets contained comparable levels of insulin, further indicat-
ing that the variant did not compromise insulin production. There-
fore, our findings indicate that the MRPP3 variant leads to altered 
cellular calcium availability that contributes to decreased insulin 
secretion causing reduced  cell sensitivity to increased glucose levels 
and potential development of insulin resistance on a high-calorie 
diet that imposes a greater requirement for insulin (Fig. 6G).
DISCUSSION
Many variants in genes encoding mitochondrial proteins identified 
by GWAS have been suggested to alter metabolism; however, func-
tional validation and mechanistic explanation of how they could 
affect metabolism for almost all of these have been lacking. Here, we 
have created a unique mouse model that functionally examines the 
role of single-nucleotide polymorphism in the nuclear encoded MRPP3 
protein (the equivalent of the human missense variant rs11156878) 
on mitochondrial function and metabolism in vivo. We found that 
the N434S variant of the MRPP3 protein resulted in a leaner phenotype 
with lower fasting glucose. However, on an HFD, this polymorphism 
reduced insulin release from the pancreas and decreased insulin 
sensitivity, indicating that the N434S variant predisposes to meta-
bolic dysfunction. The variant MRPP3 affected pancreatic function 
and the insulin-secreting pancreatic  cells most significantly, where, 
on a NCD, the N434S mice were able to mount a  cell response that 
counters insulin resistance, but under the additional stress of the HFD, 
this compensation failed. The downstream consequences of decreased 
pancreatic insulin secretion and consequent reduced circulating insulin 
levels resulted in increased lipid accumulation in the liver and reduced 
glucose uptake in skeletal muscle. Despite the role of MRPP3 in mito-
chondrial gene expression, the mutation did not affect OXPHOS 
biogenesis nor its function; instead, impaired insulin secretion was 
a consequence of compromised calcium release from mitochondria.
In the GWAS, the missense variant rs11156878 was proposed to 
modulate mitochondrial RNA sequence variation and thereby 
potentially influence basal metabolism; however, this was not 
functionally investigated (6). This was inferred most likely because 
of the roles of MRPP3 and MRPP1 in the RNase P complex in 
mitochondrial RNA processing and tRNA modification (11, 12), 
respectively. However, we found that N434S variant did not alter the 
MRPP3 catalytic function, and mitochondrial RNA processing was not 
markedly impaired. The posttranscriptional modification of the 
ninth position in mitochondrial tRNAs by the MRPP1 methyl-
transferase, which forms a complex with MRPP3 and MRPP2 in the 
RNase P complex, was also not affected. The lack of mitochondrial 
transcriptome changes in the N434S mice indicated that the metabolic 
dysfunction was not caused by changes in mitochondrial gene 
expression, consistent with the unaltered mitochondrial biogenesis 
in the mice. Although regulation of mitochondrial gene expression 
is important for energy production and its impaired function can 
lead to insulin resistance or metabolic disorders (27, 28, 40), the 
N434S variant in MRPP3 had an alternate mechanism that led to 
insulin resistance. We showed using three separate methods (BioID, 
immunoprecipitation, and bimolecular fluorescence complementation) 
that the RNase P component MRPP2 associates with the cation 
transporter LETM1, and this association is affected by the reduced 
interaction between MRPP2 and the MRPP3 N434S variant. The 
association between MRPP2 and LETM1 has been independently 
validated by recent high-throughput BioID analyses of mitochon-
drial protein interactions (41), and we found that the levels of these 
proteins are coregulated in vivo. The reduced association between 
MRPP2 and the MRPP3 N434S variant did not affect RNA process-
ing particularly as part of their role in the RNase P complex, most 
likely because the variant is away from the active site of the enzyme. 
However, the altered association and levels of LETM1 and MRPP2 
from the RNase P complex may contribute to decreased mitochondrial 
calcium and consequently affect intracellular calcium levels that are 
required for insulin secretion (31, 37), in addition to the main mito-
chondrial calcium transporters.
LETM1 and its yeast ortholog have been shown to associate with 
mitochondrial ribosomes and affect mitochondrial protein synthe-
sis (42, 43), although the changes in LETM1 levels did not affect 
mitochondrial biogenesis in the N434S mice. Instead, we only 
identified changes in intracellular calcium and circulating potassium 
levels in the pancreatic islet cells of N434S mice, suggesting that its 
role in cation transport (31, 38) was the contributing factor for in-
sulin resistance. This is consistent with the requirement for LETM1 
for mitochondrial calcium uptake and normal glucose metabolism 
(33, 34, 36). In addition, the N434S variant resulted in reduced 
potassium levels in vivo, suggesting that LETM1 may also have a role 
in mitochondrial K+-H+ exchange as it has been suggested previously 
[reviewed in (38)].
In the HFD-fed N434S mice, reduced insulin secretion correlated 
with reduced levels of BCAAs, including isoleucine, likely a conse-
quence of increased levels of MRPP2, which has an irreversible role 
in isoleucine degradation (32). Recently, it has been suggested that 
in Wolf-Hirschhorn syndrome caused by LETM1 haploinsufficiency, 
low LETM1 levels stimulate consumption of ketone bodies by an 
unknown mechanism (43). It is possible that the association and 
coregulation of LETM1 with MRPP2 mediate changes in ketogenic 
or BCAA metabolism via its role in isoleucine oxidation. Loss-of-
function mutations in MRPP2 cause severe neurological disorders 
through impaired BCAA metabolism and accumulation of toxic 
intermediates that cause mitochondrial dysfunction along with 
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(15,  32). Furthermore, patients and animal models of impaired 
BCAA metabolism are susceptible to insulin resistance and type 2 
diabetes [reviewed in (44)], features that are in common with our 
N434S mice where MRPP2 levels and BCAA were altered.
Under normal diet conditions, both wt and N434S mice pro-
duced comparable levels of insulin; however, the N434S variant 
conferred a predisposition to insulin resistance by the inability to 
effectively secrete insulin when there were excess nutrients and 
thereby long-term demand for insulin secretion. The increase of 
pancreatic islets in the HFD-fed N434S mice was likely a compensa-
tory response to the increase in nutrients, because the wt mice were 
able to meet the insulin demand in response to excess nutrient 
availability, whereas insulin secretion was reduced in the N434S 
mice in response to reduced mitochondrial calcium. This indicated 
that mitochondrial calcium availability may be required to help 
insulin secretion when there is increased demand in the presence of 
excess nutrients, as this was compromised in the pancreatic  cells 
of the N434S mice on an HFD. The requirement for mitochondrial 
calcium for insulin secretion has been shown in pancreatic cells 
where knockdown of the Na+-Ca+ exchanger altered mitochondrial 
calcium transport, resulting in delayed glucose-stimulated insulin 
release without changes in ATP production (45). Recently, reduced 
mitochondrial calcium transport has been shown to reduce insulin 
secretion (46). Under normal conditions and basal insulin levels, cellular 
calcium levels were sufficient in the N434S variant mice to meet the 
demand for insulin secretion. However, an HFD elicited a long-term 
demand for insulin secretion that may consequently require in-
creased release of calcium. The mitochondrial calcium levels in the 
N434S mice may be affected by the impaired interactions with LETM1, 
reducing the cells’ ability to mobilize calcium to stimulate insulin release, 
ultimately resulting in decreased circulating levels of insulin, reduced 
 cell sensitivity to insulin, and accumulation of lipids in the liver.
The acquisition of variants in the human genome is essential for 
adaptation to diverse nutritional availabilities and requirements. 
Extreme habitats like the Artic, for example, led to the selection in 
the Inuit population of a variant in the mitochondrial carnitine 
palmitoyltransferase protein (CPT1A), because this provides a selec-
tive advantage in the metabolism of a diet rich in fat, typical of this 
indigenous population (47). It is currently not clear why the rs11156878 
variant in MRPP3 has been selected in as high as 19% of the popu-
lation, it may be that it could provide an advantage by up-regulating 
insulin secretion under normal diet conditions. However, this ge-
netic variant predisposes to insulin resistance in a diet rich in fat 
(HFD) as mitochondria are unable to mobilize their stored calcium 
levels in the pancreas to increase insulin secretion. The mitochon-
drial Ca2+ uptake 1 and MCU proteins are the main regulators of 
mitochondrial calcium uptake, and their levels are not altered in the 
mutant mice on either diet, indicating that the normal mode of 
insulin secretion is consistent with previous findings (30, 31). Here, 
we are not challenging this model but merely suggest that LETM1, 
as it has been suggested before (33), may contribute to fine-tuning 
the release of calcium when challenged with an HFD.
Our study provides functional evidence and molecular mecha-
nisms of how a common genetic variant found predominantly in 
European populations can affect cation transport and predispose to 
reduced insulin sensitivity on a high-calorie diet. This discovery could 
help to manage the nutrition of a significant number of individuals 
within human populations to prevent or delay the onset of insulin 
resistance and potential development of type 2 diabetes.
MATERIALS AND METHODS
MRPP3 variant analyses
Aggregate allele frequencies were obtained from the National 
Center for Biotechnology Information (NCBI) database of Genotypes 
and Phenotypes from the Allele Frequency Aggregator project (build 
154, released 21 April 2020). Protein sequences from diverse species 
used were obtained from GenBank at NCBI (human, Homo sapiens, 
NP_055487.2; chimp, Pan troglodytes, XP_009425955.1; dog, Canis 
lupus familiaris, XP_547772.2; mouse, Mus musculus, NP_079649.1; rat, 
Rattus norvegicus, NP_001100200.1; chicken, Gallus gallus, XP_421241.2; 
zebrafish, Danio rerio, XP_683289.3; fruit fly, Drosophila melanogaster, 
NP_001245549.1; mosquito, Anopheles gambiae, XP_003435980.1; 
frog, Xenopus tropicalis, XP_002935379.1), and the alignment was 
produced using Clustal Omega.
The MRPP3 structure was modeled in PyMOL (Schrödinger) by 
aligning a human MRPP3 structure (PDB ID: 4XGL) to a structure of 
an engineered variant of the PPR domain of the Arabidopsis thaliana 
MRPP3 homolog (PRORP1) in complex with yeast tRNAPhe (PDB 
ID: 6LVR) using the CE algorithm to provide a final model of the 
human MRPP3 protein in complex with tRNA. The local electrostatic 
potential was modeled using the Adaptive Poisson-Boltzmann Solver 
program and visualized using PyMOL (Schrödinger).
Animals and housing
Heterozygous Mrpp3 N434S transgenic mice on a C57BL/6 N 
background were generated by the Monash Genome Modification 
Platform (MGMP) and the Australian Phenomics Network (APN). 
The N434S mutation was introduced into the Mrpp3 gene by CRISPR- 
mediated homology-dependent repair using a single-stranded DNA 
oligo nucleotide donor containing an AAT → AGC codon change. 
A silent CTA → CTG change was introduced into the neighboring 
leucine codon to enable restriction fragment length polymorphism–
based genotyping of the mutant mice. Male age- and littermate-matched 
wild-type (wt) and homozygous mutant mice (N434S) were housed 
in standard cages (45 cm by 29 cm by 12 cm) under a 12-hour light/
dark schedule (lights on 7:00 a.m. to 7:00 p.m.) in controlled environ-
mental conditions of 22° + 2°C and 50 + 10% relative humidity. NCD 
and water were provided ad libitum. HFD feed was provided ad libitum 
for 14 weeks. The feed was provided by Rat and Mouse Chow, Specialty 
Feeds, Glen Forrest, Western Australia. The study was approved by the 
Animal Ethics Committee of the University of Western Australia and per-
formed in accordance with Principles of Laboratory Care (National 
Health and Medical Research Council Australian code for the care 
and use of animals for scientific purposes, eighth edition, 2013).
Metabolic studies
Six-week-old male mice were fed either a NCD or HFD for 14 weeks. 
During this time, their body weight and food intake were moni-
tored weekly. Intraperitoneal GTT and ITT were performed in up 
to 10 mice of each genotype and diet after the mice were fasted for 
5 hours. GTTs (1 g/kg) were performed at week 12, and ITTs (1 U/kg) 
were performed at week 13. Blood glucose levels were measured using 
a glucometer (Accu-Chek Informa II, Roche). Blood was sampled 
from the tail tips at 0, 15, 30, 45, 60, 90, and 120 min after glucose or 
insulin injection. The area under or above the curve was calculated 
using the trapezoidal rule using Excel software (Microsoft). Mice 
were humanely euthanized at 20 weeks of age after 14 weeks on 
their respective diets. Methoxyflurane was used to anesthetize the 
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subsequently euthanized by cervical dislocation, and tissues were 
collected. Tissues were snap-frozen in liquid nitrogen and stored at 
−80°C. Tissues for histological analysis were either fixed in formalin 
or frozen in optimal cutting temperature (OCT) embedding medium. 
For terminal insulin testing, 20-week-old mice were injected with 
insulin (1 U/kg) and euthanized by cervical dislocation 5 min after 
the injection, followed by tissue collection (snap freezing). SCFA 
profiling was performed as described previously (48) to measure the 
concentration of acetate, butyrate, and propionate as nanomoles 
per microliter of serum. Serum was analyzed by Pathwest Laboratory 
Medicine (Nedlands, WA, Australia) for levels of albumin, ALT, 
cholesterol, TAG, LDL, HDL, and potassium (K+). Glucose uptake 
measurements were carried out in vitro with skeletal muscles isolated 
from 20-week-old HFD-fed control and mutant mice as described 
before (49). Skeletal muscles were incubated in “pregassed” (95% 
O2 and 5% CO2) Krebs-Henseleit-bicarbonate (KHB) buffer con-
taining 0.01% bovine serum albumin (BSA), 2 mM pyruvate, and 
8 mM mannitol for 30 min at 35°C. Muscles were then incubated for 
30  min at 30°C in KHB with or without 50 nM insulin. Glucose 
transport was measured after a 16-min incubation at 30°C with 1 mM 
2-deoxyglucose, 2-deoxy-d-[2, 6-3H]-glucose (0.25 Ci/ml), and 
d-[14C]-mannitol in KHB (0.16 Ci/ml) with or without 50 nM 
insulin. Muscles were trimmed and frozen in liquid nitrogen and 
later weighed and incubated for 30 min at 65°C in 250 l of 1 M 
NaOH, and at the end of the incubation, 250 l of 1 M HCl was 
added to the dissolved muscle. Samples were centrifuged at 17,000g 
for 10 min, and radioactivity was determined by scintillation counting 
for dual- label dpm in the supernatants and muscles.
Enzyme-linked immunosorbent assay
Serum (fasting) was analyzed for circulating insulin levels using an 
insulin enzyme-linked immunosorbent assay (ELISA) kit (EZRMI- 
13K; Millipore, Australia). All tissue homogenates for ELISAs were 
prepared using a lysis buffer (10 mM Hepes, 3 mM MgCl2, 14 mM 
KCl, 5% glycerol, and 0.2% IPEGAL) containing PhosSTOP Phos-
phatase Inhibitor Cocktail (Roche) and EDTA-free Complete 
protease inhibitor cocktail (Roche). Pancreas, liver, and skeletal 
muscle were analyzed for insulin levels (EZRMI-13K; Millipore). 
Data were analyzed using an online software program (https://
www.assayfit.com/).
Histology
Fresh liver tissue was frozen in OCT medium and cut using a Cryostat 
(Leica, TP1020) to 10-m thickness. All other tissues were fixed with 
10% neutral buffered formalin for 24 hours, washed in phosphate- 
buffered saline (PBS), and stored in 70% ethanol before processing. 
Tissues were then embedded in paraffin, cut in 5- or 10-m sections 
using a microtome, and transferred to positively charged slides. 
Slides were heated for 2 hours at 60°C and treated with xylene, 
xylene and ethanol (1:1), and decreasing concentrations of ethanol 
(100, 95, 80, and 60%) before they were washed and hydrated in 
distilled water. The H&E and Oil Red O staining were performed as 
described before (50). Coverslips were attached using DPX mount-
ing media (Scharlau), and images were acquired using a Nikon Ti 
Eclipse inverted microscope using a Nikon 10× or 20× objective.
Respiration
Mitochondrial respiration was evaluated as O2 consumption in iso-
lated liver as previously described (28). Mitochondria were supplemented 
with substrates 10 mM glutamate/2 mM malate (Sigma-Aldrich) and 
10 mM succinate/0.5 mM rotenone (Sigma-Aldrich), to measure aden-
osine diphosphate (ADP)–independent respiration activity (state 4). 
After addition of 1 mM ADP (Sigma-Aldrich), state 3 respiration 
activity was measured. Respiration was uncoupled by successive 
addition of carbonyl cyanide p-trifluoro-methoxyphenylhydrazone 
(FCCP) up to 3 mM to reach maximal respiration.
Fatty acid oxidation was measured from isolated liver mitochondria 
from mice fasted for 5 hours before sacrifice using the Oxygraph 2K 
respirometer (Oroboros Oxygraph-2K, Oroboros Instruments) as 
described in (51) and reviewed in (52). State 4 respiration was 
measured using 5 mM malate (Sigma-Aldrich) and 1 mM palmitoyl 
carnitine (Sigma-Aldrich), and state 3 respiration was measured using 
1 mM K-ADP (Sigma-Aldrich) and 10 mM K-succinate (Sigma- 
Aldrich). Inhibitors used included 0.5 M oligomycin (Sigma-Aldrich) 
and 2.5 M antimycin. FCCP was used as a measure of uncoupling 
and maximal respiration rate in titrations up to 3 M.
Tissue homogenate preparation
Tissue pieces (3 mm by 3 mm; liver and pancreas) were homoge-
nized in 200 l of Cell Extraction Buffer (100 mM tris, 2 mM Na3VO4, 
100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM 
EGTA, 0.1% SDS, 1 mM NaF, 0.5% deoxycholate, and 20 mM Na4P2O7), 
pH 7.4, containing PhosSTOP Phosphatase Inhibitor Cocktail 
(Roche) and EDTA-free Complete protease inhibitor cocktail 
(Roche). The homogenates were prepared using a bead beater, and 
the homogenates were centrifuged at 9000g for 5 min at 4°C. The 
previous steps were repeated until a clear tissue homogenate was 
produced. The tissue homogenate protein concentration was 
quantified using the bicinchoninic acid (BCA) assay using BSA as 
a standard.
Mitochondrial isolation
Mitochondria were isolated from homogenized liver and pancreas 
and isolated by differential centrifugation as described previously 
(12, 53). The mitochondrial protein concentration was quantified 
using the BCA assay using BSA as a standard.
Immunoblotting
Specific proteins were detected using the following rabbit monoclo-
nal antibodies: phospho-SAPK/JNK (Thr183/Tyr185, 4668), SAPK/
JNK (9252), phospho-Akt (Ser473, 4060), Akt (9272), S6 ribosomal pro-
tein (2217S), phospho–S6 ribosomal protein (4856S), glyceraldehyde 
phosphate dehydrogenase (GAPDH) (2118), LC3A/B (12741) 
MCU (14997) (Cell Signaling Technologies), and MRPP3 (HPA020459) 
(Sigma-Prestige) diluted 1:1000; rabbit polyclonal antibodies: GLUT2 
(54460) (Abcam) diluted 1:1000, GLUT4 (PA-1-1065) (Thermo Fisher 
Scientific), CPTII (OAAN00972) (Aviva System Biology) diluted 1:500, 
Letm1 (16024-1-AP) (Proteintech) diluted 1:1000, MRPP2 (HPA001432) 
(Sigma-Prestige) diluted 1:1000, LRPPRC (sc66844) (Santa Cruz 
Biotechnology) diluted 1:500, TFAM (ab131607) (Abcam) diluted 1:1000; 
mouse monoclonal antibodies: total OXPHOS Cocktail Antibody 
(ab110412), VDAC (ab14734), and SDHA (ab14715) (Abcam), diluted 
1:1000. IRDye 800CW goat anti-rabbit immunoglobulin G (IgG) or 
IRDye 680LT goat anti-mouse IgG (LI-COR Biosciences) second-
ary antibodies were used, and the immunoblots were visualized 
using an Odyssey infrared imaging system (LI-COR Biosciences). 
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RNA isolation, Northern blotting, and qRT-PCR
The tissues were snap-frozen and stored at –80°C before RNA iso-
lation, while pancreatic islets were isolated fresh using collagenase 
digestion as described below. RNA was isolated from tissues and 
pancreatic islets of Langerhans using the miRNeasy Mini kit (Qiagen) 
using an on-column RNase-free DNase digestion, and the iso-
lated RNA (4 g) was resolved on 1.2% agarose formaldehyde gels. 
Northern blotting was carried out as described previously (13) 
by transferring the RNA to 0.45 m of Hybond-N+ nitrocellu-
lose membrane (GE Lifesciences) and hybridizing using biotinylated 
oligonucleotide probes as described before (13). Streptavidin- 
linked infrared-labeled antibody [diluted 1:10,000  in 3× SSC, 
5% SDS, and 25 mM Na2HPO4 (pH 7.5)] was used to detect the 
signal and visualize the signal using the Odyssey Infrared Imag-
ing System (LI-COR Biosciences). The QuantiTect Reverse Tran-
scription Kit (Qiagen) was used to prepare complementary DNA 
(cDNA) that was used as a template for PCR. PCRs were performed 
using a Corbett Rotorgene 6000 using SensiMix SYBR mix (Bioline) 
and normalized to 18S rRNA.
RNA sequencing
RNA sequencing was performed on total pancreatic RNA isolated 
from three wt and three N434S mice fed on a NCD and a HFD. Se-
quencing was performed using the Illumina NovaSeq platform, 
according to the Illumina RNA-Seq protocol and as we have done 
previously (13). Sequenced reads were trimmed via TrimGalore 
v0.4.1 using cutadapt (54) v1.18 and FastQC (55) v0.11.8 in paired-
end mode. Biologically independent reads (three from each genotype 
and treatment) were aligned against the mouse genome [GRCm38.
p6 primary assembly (ftp://ftp.ebi.ac.uk/pub/databases/gencode/
Gencode_mouse/release_M21/gencode.vM21.primary_assembly.
annotation.gtf.gz; ftp://ftp.ebi.ac.uk/pub/databases/gencode/Gencode_
mouse/release_M21/gencode.vM21.transcripts.fa.gz) masked for 
nuclear mitochondrial sequences] with STAR v2.7.0f (56) and the 
GENCODE vM23 gene annotation with a customized mitochon-
drial annotation. Full fragment length mitochondrial coverage pro-
files were generated with samtools v1.10 (57) and bedtools v2.26.0 
(58) and normalized to total reads mapped to the mouse genome.
Small RNA sequencing
RNA sequencing was performed on total pancreatic RNA isolated 
from three wt and three N434S mice fed on a HFD. Sequencing was 
performed using the Illumina NovaSeq platform, according to the 
Illumina small RNA-Seq protocol and as we have done previously 
(13). Sequenced reads were trimmed via TrimGalore v0.6.5 using 
cutadapt (54) 0.18 and FastQC (55) v0.11.8 in paired-end mode with 
a minimum length of 18 nt. Biologically independent reads (three 
from each genotype and treatment) paired reads were merged using 
NGmerge v0.3 (59). Reads were aligned to the GRCm38.p6 genome 
sequence using STAR (56) and the GENCODE vM21 gene annotation 
(with customized mitochondrial annotations). Coverage was normalized 
to total mapped reads, and tRNA position 9 mismatch rates were 
calculated by extracting nucleotide frequencies from genomic BAM files 
with pysamstats [10] (--type variation_strand). tRNAs with an average 
raw read count of <50 across either sample group were filtered out.
BioID
MRPP3 and its N434S mutant were cloned into pcDNA3.1-MCS-
BirA(R1186)-HA. The expression of MRPP3 and MRPP3-N434S 
variant and the mitochondrial localization of the proteins were checked 
by fluorescence cell microscopy as described in (60). The BioID 
analysis was carried out as described in (61). The data were results 
from three independent biological experiments, and all significantly 
enriched proteins are shown in black and red with 0.01% false 
discovery rate significance.
Immunoprecipitation
NIH-3T3 cells were transfected with wt or N434S MRPP3 with an 
HA tag fused to the C-terminal end and incubated for 72 hours. 
Cells were crossed linked in 2 mM dithiobis(succinimidyl propio-
nate) (Life Technologies) in PBS for 30 min at room temperature 
followed by quenching in 50 mM glycine for 15  min. Cells were 
lysed in 260 mM sucrose, 100 mM KCl, 20 mM MgCl2, 10 mM tris-HCl 
(pH 7.5), 1% digitonin, and complete EDTA-free protease inhibitor 
cocktail for 30 min at 4°C followed by sonication. Lysates were in-
cubated with HA beads (Pierce) for 2 hours at 4°C. Beads were 
washed in digitonin wash buffer (same components as lysis buffer 
except with 0.1% digitonin), washed again in IGEPAL wash buffer 
(same components as lysis buffer except with 1% IGEPAL CA-630; 
Sigma-Aldrich), then eluted in 2× SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer by heating at 95°C for 10 min. 
Five microliters of input samples, taken immediately after lysis, and 
the entire final elution samples were run on SDS-PAGE gels and 
analyzed by immunoblotting as described above.
Bimolecular fluorescence complementation
NIH-3T3 cells were transfected with separate plasmids encoding LETM1 
with the VN fragment (amino acids 1 to 173 of Venus) attached to 
the C-terminal end and wt or N434S MRPP3 with the VC fragment 
(amino acids 174 to 239 of Venus) attached to the C-terminal end 
and mCherry red fluorescent protein (RFP) in a 2:2:1 ratio. Seventy- 
two hours after transfection, cells were treated with trypsin, resuspended 
in PBS + 2% fetal bovine serum (FBS), and analyzed by fluorescence- 
activated cell sorting (FACS) using a FACS Aria BDII. The analyses 
were carried out as described previously (61).
Pancreatic islet isolation
Pancreatic islets were isolated by collagenase digestion (0.9 U/ml) 
of mouse pancreata. Collagenase P (Sigma-Aldrich) was dissolved 
in cold RPMI and filtered through a 0.45-m filter before use. Mice 
were euthanized by cervical dislocation, the common bile duct was 
clamped at the junction with the duodenum, and 3 ml of ice-cold 
collagenase/RPMI was injected in the common bile duct using a sy-
ringe with a 30-G needle until the pancreas was fully inflated. Pan-
creata were incubated for 18 min in warm RPMI at 37°C before being 
disrupted by hand shaking. Digested pancreata were passed through 
a 500-m mesh before centrifugation at 193g for 5 min. Pooled acini 
and islet cells were washed twice with 50 ml of RMPI and centri-
fuged at 193g for 5 min. The pellet was resuspended in 10 ml of warm 
Histopaque-1077 (Sigma-Aldrich), overlayed with 5 ml of RPMI, 
and then centrifuged at 433g for 15 min with slow acceleration and 
without deceleration to generate a continuous density gradient. 
Islets were recovered at the interface between Histopaque-1077 and 
RPMI, transferred into 40 ml of RPMI, and centrifuged at 433g for 
5 min. The cell pellets were suspended in 3 ml of CMRL media (Thermo 
Fisher Scientific) supplemented with 10% FBS, 1% penicillin and 
streptomycin (10,000 U/ml; Gibco), and 1% of 500× l-glutamine, 
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were dispersed into single cells by trypsinization and plated in 24-well 
plates on glass slides for measurement of intracellular Ca2+ levels.
Calcium imaging and measurement
Intracellular calcium was monitored using the fluorescent indicator 
fura-2 as described previously (62). Ratiometric fluorescent (R) values 
were recorded on a Hamamatsu Orca ER digital camera attached to 
an inverted Nikon TE2000-U microscope at 1-min intervals with 
50-ms exposure (excitation, 340/380 nm; emission, 510 nm). Meta-
morph 6.3 was used to quantify fluorescent signals by manually 
tracing pancreatic islet cells. An equivalent region not containing 
cells was used as background and was subtracted. At the end of each 
experiment, ionomycin (5 M) and 5 mM Ca2+ were added to obtain 
Rmax. Medium was then replaced with calcium-free imaging solu-
tion supplemented with EGTA (3 mM) to obtain Rmin. Intracellular 
calcium [Ca2+]i (nM) was calculated from ratiometric fluorescent 
values (R) according to the equation
  [Ca] i =  K d . b . (R‐  R min ) / ( R max ‐R) 
where Rmin = minimum ratiometric fluorescence value, Rmax = 
maximum ratiometric fluorescent value, b (minimum fluorescence 
value at 380 nm/maximum fluorescent intensity at 380 nm), and Kd 
(dissociation constant) = 224 (nM) as determined previously (63).
Mitochondrial Ca2+ was monitored in pancreatic islet cells using 
the fluorescent indicator Rhod-2 (Thermo Fisher Scientific) as de-
scribed previously (64,  65). The cells were incubated in 140 mM 
NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.5 mM MgCl2, and 5.5 mM 
Hepes (pH 7.4), supplemented with 1 M Rhod-2 for 20  min at 
37°C. The buffer was replaced with fresh prewarmed buffer and in-
cubated for a further 30 min at 37°C. Fluorescent images were taken 
at 37°C before and after addition of 10 mM glucose using an Andor 
Zyla SCMOS 5.5 MP camera attached to an inverted Nikon TE2000-U 
microscope, driven by Metamorph 7.10 software (excitation, 545 nm; 
emission, 620 nm; interval, 0.5 min; exposure, 50 ms). At the end of 
each incubation, 5 M ionomycin and 5 mM calcium were added to 
achieve maximum fluorescence (Fmax). Once steady state was 
achieved, the buffer was removed and replaced with prewarmed 
calcium-free 140 mM NaCl, 5.4 mM KCl, 0.5 mM MgCl2, 5.5 mM 
Hepes, 3 mM EGTA, and 11 mM glucose (pH 7.4) buffer, to achieve 
minimum fluorescence (Fmin). Fluorescent images were quantified 
using Metamorph 7.10. The cells were manually traced to quantify 
the fluorescent signal. An equivalent area not containing cells was 
used as background and subtracted from matched cells. All re-
sponses were expressed as a percent increase from pretreatment 
(basal) fluorescent values (F) according to the following equation
  Rhod‐2 = [(F‐  F min ) / ( F max ‐  F min ) ] 
Glucose stimulation of insulin secretion
The glucose stimulation of insulin secretion assay was performed 
24 hours after the pancreatic islets from mouse were isolated and 
cultured in complete CMRL media [10% FBS, 1% penicillin and 
streptomycin (10,000 U/ml; Gibco), and 1% of 500× l-glutamine]. 
Ten islets per mouse were collected and transferred into a 24-well plate 
where they were washed twice with 0.5 ml of prewarmed Krebs buf-
fer (pH 7.4) (137 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
MgSO4-7H2O, 2.5 mM CaCl2-2H2O, 25 mM NaHCO3, 10 mM 
Hepes, and 0.25% fat-free BSA). After the wash, the islets were incu-
bated for 1 hour at 37°C with 200 l of 5.5 mM glucose. The super-
natant was collected, centrifuged at 376g for 5 min, and stored for 
determination of basal insulin content. The islets were then washed 
twice with 0.5 ml of Krebs buffer and incubated for 1 hour at 37°C 
with 200 l of 16.7 mM glucose. The supernatant was collected, cen-
trifuged at 376g for 5 min, and stored for determination of insulin 
secretion after glucose stimulation. The islets were then collected in 
0.5 ml of Krebs buffer centrifuged at maximum speed for 5 min, and 
the pellet was stored for determination of insulin levels. Insulin levels 
were determined by using a commercial ELISA kit (Merck Millipore, 
EZRMI-13K), and the data were analyzed using an online software 
program (https://www.assayfit.com/).
Mitochondrial membrane potential measurements
Pancreatic islets were trypsinized to obtain single viable cells and 
seeded overnight in a black 96-well plate at a density of 12,500 cells 
per well in 200 l of CMRL complete media. For each mouse, three 
wells were set up for FCCP treatment and six wells for nontreated 
cells. The next day, the islets were treated with 10 l of 1 mM FCCP 
and placed for 10 min at 37°C, 5% CO2. The medium was next removed 
and cells were washed twice with media not containing FBS. A fresh 
JC-1 50 M staining solution was prepared on the day in Dulbecco’s 
modified Eagle’s medium in the absence of FBS and added at a 
volume of 50 l per well to the same wells previously treated with 
FCCP and to untreated cells. Islets were then left in incubation for 
1 hour protected from light at 37°C, 5% CO2. After the staining solu-
tion was removed, the cells were washed with 200 l of PBS/5% BSA 
and left at 5 min at 37°C. Next, the wash solution was removed 
and 100 l of PBS was added per well before proceeding to the read-
ing. Fluorescence emission was measured at 520/590  nm using a 
CLARIOstar plate reader.
Amino acid measurements
Amino acids were extracted in 50:50 water/methanol by homoge-
nizing 20 mg of pancreas tissue or serum from wt and N434S mice 
fed on a NCD or a HFD, using a bead beater. The solvent was ana-
lyzed by targeted reversed-phase high-speed quantitative ultraper-
formance liquid chromatography–tandem mass spectrometry analysis 
as described previously (66).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/ 
sciadv.abi7514
View/request a protocol for this paper from Bio-protocol.
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